Meridian Initiates Clinical Trials for New Neonatal Saliva CMV illumigene Test
CINCINNATI, Aug. 09, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has initiated clinical trials for a new illumigene CMV molecular amplification test. This assay is designed to specifically detect the congenital Cytomegalovirus (CMV) infection in newborns from saliva. Presently, there is no FDA-cleared test for CMV screening in newborns. Meridian has enrolled an […]